Affiliation:
1. Xinjiang Medical University
2. The First Affiliated Hospital of Xinjiang Medical University
3. Youai Hospital
Abstract
Abstract
Background
Despite prostate cancer's (PCa) highly variable behavior and unclear response to immunotherapy, the importance of NK cells isn't comprehensively studied. Our study aimed to use a robust computational framework to consider NK cell marker gene signatures (NKCMGS) from 1,072 global PCa patients, intending to establish a reliable biomarker that can prognose and predict immunotherapy response.
Methods
NK cell-related biomarkers were studied in PRAD patients from six worldwide cohorts, creating a reliable NKCMGS biomarker using 101 genes and varied machine learning techniques. NKCMGS was further analyzed immunologically, providing new immunotherapy response and prognosis perspectives.
Results
The NKCMGS integrated 13 key genes, effectively classifying patients into high- and low-risk groups. Survival curves drawn from NKCMGS scores, age, T stage, and Gleason scores, established the reliable prognostic trait of NKCMGS. Biologically, high-scored NKCMGS indicated enhanced fatty acid and β-alanine metabolism pathways, while low scores showed enrichment in DNA repair and replication, homologous recombination, and cell cycle pathways. Moreover, low-risk patients demonstrated higher drug sensitivity, thus suggesting the potential of NKCMGS in predicting immune checkpoint inhibitor effectiveness.
Conclusion
Our robust machine learning framework, integrated with NKCMGS, show significant potential for providing personalized risk assessment and valuable treatment strategies for PCa patients.
Publisher
Research Square Platform LLC
Reference62 articles.
1. Control of Metastasis by NK Cells;A L;Cancer Cell,2017
2. Regulation of prostate cancer progression by the tumor microenvironment;A SLS;Cancer Letters,2016
3. Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients;Ali HEA;Scientific Reports,2018
4. Past, Current, and Future of Immunotherapies for Prostate Cancer;AN B;Frontiers in Oncology,2019
5. Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme β-galactosylceramidase;Belleri M;Biochimica et biophysica acta. Reviews on cancer,2022